Clinical trial Intelligence for contract research organizations
We help CROs win business and enhance drug development services. Make better-informed decisions while bidding on and implementing clinical trials.
There are some trials that could be great for your business and others that might not be. But without high-quality intelligence, it can be hard to assess or maximize a trial’s potential.
How we help
Our thorough and extensive clinical trial intelligence for CROs will help your organization:
We’ll help you identify companies active in your territory and their phases of development. Spot where to run trials, with our data on where comparator trials have been approved and the availability of regional investigators.
You can size up competing trials, because we monitor and benchmark them, prioritizing investigators and tracking enrollment. And to help you mitigate risks, we can provide intelligence on safety issues faced by trials of similar designs.
Citeline, Datamonitor Healthcare
Join our free 24-hour interactive webinar series on 21 July that will cover the latest insights and learning on COVID-19 from across the global Pharma and Biomedtech industry.
We conducted a survey to 100 clinical trial investigators to gauge expectations for future clinical research. Your free infographic provides key insight and analysis to help you understand the future clinical trial landscape.
Don’t miss your view into the NAS that made an impact last year, your follow-up to the Pharma R&D Annual Review 2020 webinar.
Recently, Pharma Intelligence brought you the Pharma R&D Annual Review 2020 Webinar, followed up with the NAS (New Active Substances) Infographic. We now invite you to go even deeper into pharma R&D successes for 2019 with your free copy of the NAS Supplement.
The pharma industry is moving into a new decade, and Pharmaprojects is here with insights into what we can expect in the year ahead. Join us to examine the trends and pipelines in a new level of granular detail. Get a taste of the direction R&D is heading in the Pharma R&D Annual Review Webinar.
To mark Pharmaprojects’ 40th year as the leading drug intelligence service, celebrate with us as we revisit key events and milestones for Pharmaprojects and the biopharma industry as a whole.
Access this infographic which focuses on Gilead’s drug Remdesivir which currently shows the greatest promise for the likelihood of approval as a possible treatment to effectively treat the virus. The infographic highlights the drug summary and profile, the number of patients in each trial phase, and the history of events that have moved this product through the development process.
Using the new, granular datapoints in Pharmaprojects, Senior Director Ian Lloyd presents his expert insights into pharma’s R&D activities over the past year and what they may mean for the pipeline during the year to come. The 27th instalment of the Annual Review, this version takes advantage of improvements to Pharmaprojects’ data granularity to bring you details on pharma R&D trends
Using new, granular data from Pharmaprojects, part of the Citeline suite of tools, this infographic will explore: The 2020 Pipeline by Phase Top Companies Mechanisms and Targets Types of Pipeline Drugs
Gain vital insight into study feasibility, site selection, and investigator prioritization with granular data from the new Informa Pharma Intelligence Patient Proximity API. Protect yourself against costly trial delays by using it to choose the right investigators with relevant and sizable patient proximity.
Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet...
Access the infographic below which explores the number of treatment drugs for COVID-19 currently in clinical trials or in development, events including progress updates, partnerships, regulatory and trial announcements etc, and the number of articles published on COVID-19 as of March 3, 2020. This data has been tracked and reported via Informa Pharma Intelligence’s clinical, regulatory and commercial data and analytics, and news and insight tools including Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet, Medtech Insight, and Generics Bulletin etc.
Get a deeper understanding of breast cancer clinical trials initiated since 2014 and what the trends have meant for strategies in this area, with this free whitepaper from Citeline.
A clear view of the past is often the surest way to plan for the future. The annual analysis of Phase I-III clinical trials from Citeline’s Trialtrove reveals the priorities and strategies of the biopharma industry. This infographic lets you clearly see the players, trials, and trends.
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: